The following is a summary of the Varex Imaging Corporation (VREX) Q2 2024 Earnings Call Transcript:

Financial Performance:

• Varex reported Q2 revenue of $206 million, down 10% year-over-year with the medical segment declining by 15% and the industrial segment increasing 6%.

• Non-GAAP gross margin remained constant at 33% year-over-year, while non-GAAP earnings per share was $0.16, down from $0.26 last year.

• The company's cash and marketable securities rose by $68 million, reaching a total of $190 million compared to the same period in fiscal 2023.

• Despite slower market demand for their products, Varex successfully closed a $175 million financing, ensuring a strong cash liquidity.

Business Progress:

• Medical sales were negatively impacted due to cautious purchasing behaviours and softness in the Chinese market, but the sale of CT tubes improved.

• Industrial sales maintained trend with a boost from cargo inspection products and industrial tubes.

• Varex made progress in their photon-counting technology, securing it as a significant income source for the future.

• Success with collaborative projects under the Horizon Europe program enhanced Varex's photon-counting technology.

• Varex projects their photon-counting technology to contribute over $100 million in revenue over the next 5 years and more than $150 million annually by fiscal 2029.

• The company foresees a steady uptake of their photon counting detectors technology bringing considerable benefits to the industrial side of their business.

• Focus on image processing and construction software development, expected to benefit from the uptake of photon counting technology.

More details: Varex Imaging IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.